Genetic Information

Gene & Transcript Details

Gene
ATM
Transcript
NM_000051.4 MANE Select
Total Exons
Reference Sequence
NC_000011.9
Alternative Transcripts
IDStatusDetails
NM_000051.3 RefSeq Select 13147 nt | 386–9556
NM_000051.4 MANE Select 12915 nt | 151–9321

Variant Details

HGVS Notation
NM_000051.4:c.419A>T
Protein Change
D140V
Location
Exon 5 (Exon 5 of )
5
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Unknown
0 publications
Clinical Statement

""

COSMIC Somatic Evidence

Open
COSMIC ID
Recurrence
0 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene ATM.

Functional Studies & Therapeutic Relevance

Functional Summary

The ATM D140V variant has not been functionally characterized.

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.06 -87 bp
- Donor Loss (DL) 0.04 77 bp
+ Acceptor Gain (AG) 0.0 -77 bp
+ Donor Gain (DG) 0.01 411 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PVS1

PVS1 (Not Applied)

According to VCEP guidelines for PVS1: Very strong/strong/moderate/supporting use for null variants in ATM. The evidence for this variant shows it is a missense change (D140V), not a null variant. Therefore, this criterion is not applied.

PS1

PS1 (Not Applied)

According to standard ACMG guidelines for PS1: "Same amino acid change as a previously established pathogenic variant regardless of nucleotide change." The evidence for this variant shows no prior pathogenic D140X change at this residue. Therefore, this criterion is not applied.

PS2

PS2 (Not Applied)

According to standard ACMG guidelines for PS2: "De novo (both maternity and paternity confirmed)..." The evidence for this variant shows no de novo data. Therefore, this criterion is not applied.

PS3

PS3 (Not Applied)

According to VCEP guidelines for PS3 (gene-specific): use when a variant fails to rescue an ATM-specific feature and radiosensitivity. The evidence for this variant shows no functional studies have been performed. Therefore, this criterion is not applied.

PS4

PS4 (Not Applied)

According to standard ACMG guidelines for PS4: "The prevalence of the variant in affected individuals is significantly increased compared to controls." No case-control data are available. Therefore, this criterion is not applied.

PM1

PM1 (Not Applied)

According to standard ACMG guidelines for PM1: "Located in a mutational hot spot and/or critical and well-established functional domain without benign variation." The evidence for this variant shows D140 is not in a recognized ATM mutational hotspot. Therefore, this criterion is not applied.

PM2

PM2 (Moderate)

According to standard ACMG guidelines for PM2: "Absent from controls (or at extremely low frequency if recessive) in population databases." The evidence for this variant shows it is absent from gnomAD and other population databases. Therefore, this criterion is applied at Moderate strength.

PM3

PM3 (Not Applied)

According to VCEP guidelines for PM3 (recessive): "Detected in trans with a pathogenic variant for a recessive disorder." There is no information on a second pathogenic ATM allele or phase. Therefore, this criterion is not applied.

PM4

PM4 (Not Applied)

According to standard ACMG guidelines for PM4: "Protein length changes due to in-frame indels or stop-loss variants." This is a missense variant without length change. Therefore, this criterion is not applied.

PM5

PM5 (Not Applied)

According to standard ACMG guidelines for PM5: "Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before." No pathogenic missense at D140 is reported. Therefore, this criterion is not applied.

PM6

PM6 (Not Applied)

According to standard ACMG guidelines for PM6: "Assumed de novo, without confirmation of paternity and maternity." No such data are available. Therefore, this criterion is not applied.

PP1

PP1 (Not Applied)

According to standard ACMG guidelines for PP1: "Cosegregation with disease in multiple affected family members..." No segregation data are available. Therefore, this criterion is not applied.

PP2

PP2 (Not Applied)

According to standard ACMG guidelines for PP2: "Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease." ATM has known pathogenic and benign missense variation; this does not strongly support benign interpretation. Therefore, this criterion is not applied.

PP3

PP3 (Not Applied)

According to VCEP guidelines for PP3: "Protein: REVEL >.7333; RNA: impact on splicing by well-established in silico predictor." The evidence shows mixed computational predictions and SpliceAI score of 0.06 predicting no splice impact. REVEL is not available. Therefore, this criterion is not applied.

PP4

PP4 (Not Applied)

According to standard ACMG guidelines for PP4: "Patient's phenotype or family history is highly specific for a disease with a single genetic cause." No phenotype data are provided. Therefore, this criterion is not applied.

PP5

PP5 (Not Applied)

According to standard ACMG guidelines for PP5: "Reputable source reports variant as pathogenic." The variant is not in ClinVar or other databases. Therefore, this criterion is not applied.

BA1

BA1 (Not Applied)

According to standard ACMG guidelines for BA1: "Allele frequency is >5% in population databases." The variant is absent. Therefore, this criterion is not applied.

BS1

BS1 (Not Applied)

According to VCEP guidelines for BS1: "Filtering Allele Frequency >.05%." The variant is absent. Therefore, this criterion is not applied.

BS2

BS2 (Not Applied)

According to standard ACMG guidelines for BS2: "Observed in healthy adult individuals for a dominant disorder..." No such data are available. Therefore, this criterion is not applied.

BS3

BS3 (Not Applied)

According to VCEP guidelines for BS3: "Use when a variant rescues an ATM-specific feature and/or radiosensitivity." No functional data are available. Therefore, this criterion is not applied.

BS4

BS4 (Not Applied)

According to standard ACMG guidelines for BS4: "Lack of segregation in affected members of a family." No family data are available. Therefore, this criterion is not applied.

BP1

BP1 (Not Applied)

According to standard ACMG guidelines for BP1: "Missense variant in a gene for which primarily truncating variants are known to cause disease." ATM has known pathogenic missense variants. Therefore, this criterion is not applied.

BP2

BP2 (Not Applied)

According to VCEP guidelines for BP2: "Use ATM PM3/BP2 table for cis/trans observations." No such data are available. Therefore, this criterion is not applied.

BP3

BP3 (Not Applied)

According to standard ACMG guidelines for BP3: "In-frame deletions/insertions in a repetitive region without a known function." This is a missense variant. Therefore, this criterion is not applied.

BP4

BP4 (Not Applied)

According to VCEP guidelines for BP4: "Protein Analysis: Metapredictor REVEL score ≤.249 or RNA: no splice impact by well-established predictor." REVEL is unavailable and computational evidence is mixed. Therefore, this criterion is not applied.

BP5

BP5 (Not Applied)

According to standard ACMG guidelines for BP5: "Variant found in a case with an alternate molecular basis for disease." No such data are available. Therefore, this criterion is not applied.

BP6

BP6 (Not Applied)

According to standard ACMG guidelines for BP6: "Reputable source reports variant as benign." No such reports exist. Therefore, this criterion is not applied.

BP7

BP7 (Not Applied)

According to standard ACMG guidelines for BP7: "Synonymous variant for which splicing prediction algorithms predict no impact and nucleotide is not highly conserved." This is a missense variant. Therefore, this criterion is not applied.